An overview of the identification and management of the metabolic syndrome in chiropractic practice

Journal of Chiropractic Medicine

Volumn 13, Issue 3, 2014, Pages 210-219

  Seaman, David R ^a   Palombo, Adam D ^b  

^a NATIONAL UNIVERSITY OF HEALTH SCIENCES   (United States)

^b First Religious Society Newburyport   (United States)

Author keywords

Hyperglycemia; Inflammation; Insulin resistance; Metabolic syndrome X; Weight loss

Indexed keywords

EID: 85027948752     PISSN: 15563707     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcm.2014.07.002     Document Type: Article

References (117)

1. Kaur J. A comprehensive review on metabolic syndrome. Cardiol Res Pract 2014, 943162. http://dx.doi.org/10.1155/2014/943162
2. Ford E.S., Giles W.H., Dietz W.H. Prevalence of the metabolic syndrome among US adults. Findings from the Third National Health and Nutrition Examination Survey. J Am Med Assoc 2006, 287:356-359.
3. Boyle J.P., Thompson T.J., Gregg E.W., Barker L.E., Williamson D.F. Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence. Popul Health Metr 2010, 8:29. http://dx.doi.org/10.1186/1478-7954-8-29
4. Centers for Disease Control and Prevention Adult Obesity Facts 2014, [Internet], CDC, Atlanta, [Available from http://www.cdc.gov/obesity/data/adult.html].
5. Ogden C.L., Carroll M.D., Kit B.K., Flegal K.M. Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA 2014, 311(8):806-814.
6. Riksman J.S., Williamson O.D., Walker B.F. Delineating inflammatory and mechanical sub-types of low back pain: a pilot survey of fifty low back pain patients in a chiropractic setting. Chiropr Man Therap 2011, 19(1):5. http://dx.doi.org/10.1186/2045-709X-19-5
7. Dobretsov M., Ghaleb A.H., Romanovsky D., Pablo C.S., Stimers J.R. Impaired insulin signaling as a potential trigger of pain in diabetes and prediabetes. Int Anesthesiol Clin 2007, 45(2):95-105.
8. Mantyselka P., Miettola J., Niskanen L., Kumpusalo E. Glucose regulation and chronic pain at multiple sites. Rheumatology 2008, 47(8):1235-1238.
9. Mäntyselkä P., Miettola J., Niskanen L., Kumpusalo E. Persistent pain at multiple sites-connection to glucose derangement. Diabetes Res Clin Pract 2009, 84(2):e30-e32.
10. Mantyselka P., Kautianen H., Vanhala M. Prevalence of neck pain in subjects with metabolic syndrome-a cross-sectional population-based study. BMC Musculoskelet Disord 2010, 11:171. 10.1186/1471-2474-11-171.
11. Rechardt M., Shiri R., Karppinen J., Jula A., Heliövaara M., Viikari-Juntura E. Lifestyle and metabolic factors in relation to shoulder pain and rotator cuff tendinitis: a population-based study. BMC Musculoskelet Disord 2010, 11:165.
12. Gaida J.E., Alfredson L., Kiss Z.S., Wilson A.M., Alfredson H., Cook J.L. Dyslipidemia in Achilles tendinopathy is characteristic of insulin resistance. Med Sci Sports Exerc 2009, 41:1194-1197.
13. Malliaras P., Cook J.L., Kent P.M. Anthropometric risk factors for patellar tendon injury among volleyball players. Br J Sports Med 2007, 41:259-263.
14. Skrzynski S. DSC study of collagen in disc disease. J Biophys 2009, 2009:819635. http://dx.doi.org/10.1155/2009/819635
15. Luevano-Contreras C., Chapman-Novakofski K. Dietary advanced glycation end products and aging. Nutrients 2010, 2(12):1247-1265. [2009;2009:819635].
16. Abate M., Schiavone C., Pelotti P., Salini V. Limited joint mobility (LJM) in elderly subjects with type II diabetes mellitus. Arch Gerontol Geriatrics 2011, 53:135-140.
17. Sakellaridis N. The influence of diabetes mellitus on lumbar intervertebral disk herniation. Surg Neurol 2006, 66:152-154.
18. Shepherd P.R., Kahn B.B. Glucose transporters and insulin action: implications for insulin resistance and diabetes mellitus. New Eng J Med 1999, 341(4):248-257.
19. Abdul-Ghani M.A., DeFronzo R.A. Pathogenesis of insulin resistance in skeletal muscle. J Biomed Biotechnol 2010, 19. [Article ID 476279]. http://dx.doi.org/10.1155/2010/476279
20. American Heart Association About metabolic syndrome 2014, [Internet], The Association, Dallas, [Available from http://www.heart.org/HEARTORG/Conditions/More/MetabolicSyndrome/About-Metabolic-Syndrome_UCM_301920_Article.jsp].
21. Hotamisligil G.S. Inflammation and metabolic disorders. Nature 2006, 444:860-867.
22. Glass C.K., Olefsky J.M. Inflammation and lipid signaling in the etiology of insulin resistance. Cell Metab 2012, 15(5):635-645.
23. Reaven G.M. All obese individuals are not created equal: insulin resistance is the major determinant of cardiovascular disease in overweight/obese individuals. Diabetes Vasc Dis Res 2005, 2:105-112.
24. Ritov V.B., Menshikova E.V., He J., Ferrell R.E., Goodpaster B.H., Kelley D.E. Deficiency of subsarcolemmal mitochondria in obesity and type 2 diabetes. Diabetes 2005, 54:8-14.
25. Corcoran M.P., Lamon-Fava S., Fielding R.A. Trans fats and insulin resistance: skeletal muscle lipid deposition and insulin resistance: effect of dietary fatty acids and exercise. Am J Clin Nutr 2007, 85:662-677.
26. Schipper H.S., Prakken B., Kalkhoven E., Boes M. Adipose tissue-resident immune cells: key players in immunometabolism. Trends Endocrinol Metab 2012, 23:407-415.
27. Antuna-Puente B., Feve B., Fellahi S., Bastard J.P. Adipokines: the missing link between insulin resistance and obesity. Diabetes Metab 2008, 34:2-11.
28. Grimble R.F. Inflammatory status and insulin resistance. Curr Opin Clin Nutr Metab Care 2003, 5:551-559.
29. Tilg H., Moschen A.R. Inflammatory mechanisms in the regulation of insulin resistance. Mol Med 2008, 3-4:222-231.
30. Johnson D.R., O'Conner J.C., Satpathy A., Freund G.G. Cytokines in type 2 diabetes. Vitam Horm 2006, 74:405-441.
31. Ridker P.M., Wilson P.W., Grundy S.M. Should C-reactive protein be added to the metabolic syndrome and to assessment of global cardiovascular risk?. Circulation 2004, 109:2818-2825.
32. Gelaye B., Revilla L., Lopez T., et al. Association between insulin resistance and c-reactive protein among Peruvian adults. Diabetol Metab Syn 2010, 2:30.
33. Singh V.P., Bali A., Singh N., et al. Advanced glycation end products and diabetic complications. Korean J Physiol Pharmacol 2014, 18(1):1-14.
34. Baker R.G., Hayden M.S. NF-kB, inflammation and metabolic disease. Cell Metab 2011, 13(1):11-22.
35. Purkayastha S., Cair D. Neuroinflammatory basis of metabolic syndrome. Mol Metab Nov 2013, 2(4):356-363.
36. Ehse J.A., Boni-Schnetzler M., Faulenbach M., Donath M.Y. Macrophages, cytokines and beta-cell death in type 2 diabetes. Biochem Soc Trans 2008, 36(3):340-342.
37. Boni-Schnetzler M., Ehses J.A., Faulenbach M., Donath M.Y. Insulitis in type 2 diabetes. Diabetes Obes Metab 2008, 10(Suppl. 4):201-204.
38. Donath M.Y., Schumann D.M., Faulenbach M., Ellingsgaard H., Perren A., Ehses J.A. Islet inflammation in type 2 diabetes: from metabolic stress to therapy. Diabetes Care 2008, 31(Suppl. 2):S161-S164.
39. Donath M.Y., Boni-Schnetzler M., Ellingsgaard H., Ehses J.A. Islet inflammation impairs the pancreatic beta-cell in type 2 diabetes. Physiology 2009, 24:325-331.
40. Harford K.A., Reynolds C.M., McGillicuddy F.C., Roche H.M. Fats, inflammation and insulin resistance: insights to the role of macrophage and T-cell accumulation in adipose tissue. Proc Nutr Soc 2011, 70:408-417.
41. Munoz A., Costa M. Nutritionally mediated oxidative stress and inflammation. Oxid Med Cell Longev 2013, 2013:610950. http://dx.doi.org/10.1155/2013/610950
42. Wisse B.E., Schwartz M.W. Does hypothalamic inflammation cause obesity?. Cell Metab 2009, 10(4):241-242.
43. Purkayastha S., Cair D. Neuroinflammatory basis of metabolic syndrome. Mol Metab Nov 2013, 2(4):356-363.
44. Calegari V.C., Torsoni A.S., Vanzela E.C., Araújo E.P., Morari J., Zoppi C.C., et al. Inflammation of the hypothalamus leads to defective pancreatic islet function. J Biol Chem 2011, 286(15):12870-12880.
45. Cordain L., Eaton S.B., Sebastian A., et al. Origins and evolution of the Western diet: health implications for the 21st century. Am J Clin Nutr 2005, 81:341-354.
46. Barclay A.W., Petocz P., McMillan-Price J., et al. Glycemic index, glycemic load, and chronic disease risk-a meta-analysis of observational studies. Am J Clin Nutr 2008, 87:627-637.
47. Facchini F.S., Hua N., Abbasi F., Reaven G.M. Insulin resistance as a predictor of age-related disease. J Clin Endocrinol Metab 2001, 86:3574-3578.
48. Lin H., Lee B., Ho Y., et al. Postprandial glucose improves the risk prediction of cardiovascular death beyond the metabolic syndrome in the nondiabetic population. Diabetes Care Sep 2009, 32(9):1721-1726.
49. O'Keefe J.H., Bell D.S. Postprandial hyperglycemia/hyperlipidemia (postprandial dysmetabolism) is a cardiovascular risk factor. Am J Cardiol 2007, 100:899-904.
50. Cao H. Adipocytokines in obesity and metabolic disease. J Endocrinol 2014, 220(2):T47-T59.
51. Nah S.S., Choi I.Y., Lee C.K., et al. Effects of advanced glycation end products on the expression of COX2, PGE2 and NO in human osteoarthritic chondrocytes. Rheumatology (Oxford) 2008, 47(4):425-431.
52. Abate M., Schiavone C., Pelotti P., Salini V. Limited joint mobility (LJM) in elderly subjects with type II diabetes mellitus. Arch Gerontol Geriatr 2011, 53:135-140.
53. Robinson D., Mirovsky Y., Halperin N., Evron Z., Nevo Z. Changes in proteoglycans of intervertebral disc in diabetic patients: a possible cause of increased back pain. Spine 1998, 23:849-856.
54. Sakellaridis N., Androulis A. Influence of diabetes mellitus on cervical intervertebral disc herniation. Clin Neurol Neurosurg 2008, 110:810-812.
55. Jhawar B.S., Fuchs C.S., Colditz G.A., Stampfer M.J. Cardiovascular risk factors for physician-diagnosed lumbar disc herniation. Spine J 2006, 6:684-691.
56. Lotan R., Oron A., Anekstein Y., Shalmon E., Mirovsky Y. Lumbar stenosis and systemic diseases: is there any relevance. J Spinal Disord Tech 2008, 21:247-251.
57. Anekstein Y., Smorgick Y., Lotan R., et al. Diabetes mellitus as a risk factor for the development of lumbar spinal stenosis. Isr Med Assoc J 2010, 12:16-20.
58. Choi K.M. Sarcopenia and sarcopenic obesity. Endocrinol Metab (Seoul) 2013, 28(2):86-89.
59. D'hooge R., Cagnie B., Crombez G., et al. Increased intramuscular fatty infiltration without differences in lumbar muscle cross-sectional area during remission of unilateral recurrent low back pain. Man Ther 2012 Dec, 17(6):5584-5588.
60. Chen Y.Y., Pao J.L., Liaw C.K., et al. Image changes of paraspinal muscles and clinical correlations in patients with unilateral lumbar spinal stenosis. Eur Spine J 2014, 23(5):999-1006.
61. Kim Y., Park H. Does regular exercise without weight loss reduce insulin resistance in children and adolescents?. In J Endocrinol 2013, 402592. [Epub 2013 Dec 12]. http://dx.doi.org/10.1155/2013/402592
62. Strasser B., Siebert U., Schobersberger W. Resistance training in the treatment of the metabolic syndrome: a systematic review and meta-analysis of the effect of resistance training on metabolic clustering in patients with abnormal glucose metabolism. Sports Med 2010, 40:397-415.
63. Sharman M.J., Volek J.S. Weight loss leads to reductions in inflammatory biomarkers after a very-low-carbohydrate diet and a low-fat diet in overweight men. Clin Sci (Lond) 2004, 13:365-369.
64. Teng K.T., Chang C.Y., Chang L.F., et al. Modulation of obesity-induced inflammation by dietary fats: mechanisms and clinical evidence. Nutr J 2014, 13:12. http://dx.doi.org/10.1186/1475-2891-13-12
65. Tzotzas T., Evangelou P., Kiortsis D.N. Obesity, weight loss and conditional cardiovascular risk factors. Obes Rev 2011, 12(5):e282-e289.
66. Stone N., Robinson J., Lichtenstein A.H., et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. Circulation 2014, 129(25 Suppl 2):S1-S45.
67. Pérez-Guisado J., Muñoz-Serrano A. A pilot study of the Spanish ketogenic Mediterranean diet: an effective therapy for the metabolic syndrome. J Med Food 2011, 14(7-8):681-687.
68. Pérez-Guisado J., Muñoz-Serrano A., Alonso-Moraga A. Spanish ketogenic Mediterranean diet: a healthy cardiovascular diet for weight loss. Nutr J 2008, 7:30. http://dx.doi.org/10.1186/1475-2891-7-30.
69. Jonsson T., Granfeldt Y., Lindeberg S., et al. Subjective satiety and other experiences of a Paleolithic diet compared to a diabetes diet in patients with T2DM. Nutr J 2013, 12:105. http://dx.doi.org/10.1186/1475-2891-12-105
70. Jonsson T., Granfeldt Y., Ahren B., et al. Beneficial effects of a Paleolithic diet on cardiovascular risk factors in T2DM: a randomized cross-over pilot study. Cardiovasc Diabetol 2009, 8:35. http://dx.doi.org/10.1186/1475-2840-8-35.
71. Nicklas B.J., You T., Pahor M. Behavioural treatments for chronic system inflammation: effects of dietary weight loss and exercise training. Can Med Assoc J 2005, 172(9):1199-1209.
72. O'Keefe J.H., Gheewala N.M., O'Keefe J.O. Dietary strategies for improving post-prandial glucose, lipids, inflammation, and cardiovascular health. J Am Coll Cardiol 2008, 51:249-255.
73. O'Keefe J.H., Cordain L. Cardiovascular disease resulting from a diet and lifestyle at odds with our Paleolithic genome: how to become a 21st-century hunter-gatherer. Mayo Clin Proc 2004, 79(1):101-108.
74. Ames B.N. Low micronutrient intake may accelerate the degenerative diseases of aging through allocation of scarce micronutrients by triage. Proc Natl Acad Sci U S A 2006, 103(47):17589-17594.
75. Holick M.F., Chen T.C. Vitamin D deficiency: a worldwide problem with health consequences. Am J Clin Nutr 2008, 87:1080S-1086S. [Suppl.].
76. Toubi E., Shoenfeld Y. The role of vitamin D in regulating immune responses. Isr Med Assoc J 2010, 12(3):174-175.
77. King D.E., Mainous A.G., Geesey M.E., Egan B.M., Rehman S. Magnesium supplement intake and C-reactive protein levels in adults. Nutr Res 2006, 26:193-196.
78. Rosanoff A., Weaver C.M., Rude R.K. Suboptimal magnesium status in the United States: are the health consequences underestimated?. Nutr Rev 2012, 70(3):153-164.
79. Simopoulos A.P. Omega-3 fatty acids in inflammation and autoimmune diseases. J Am Coll Nutr 2002, 21(6):495-505.
80. Simopoulos A.P. The importance of the omega-6/omega-3 fatty acid ratio in cardiovascular disease and other chronic diseases. Exp Biol Med 2008, 233:674-688.
81. Fung G.J., Steffen L.M., Zhou X., et al. Vitamin D intake is inversely related to risk of developing metabolic syndrome in African American and white men and women over 20 y: the Coronary Artery Risk Development in Young Adults study. Am J Clin Nutr 2012, 96(1):24-29. [Published online 2012 May 30].
82. Palomer X., Gonzalez-Clemente J.M., Blanco-Vaca F., Mauricio D. Role of vitamin D in the pathogenesis of type 2 diabetes mellitus. Diabetes Obes Metab 2008, 10:185-197.
83. Guadarrama-Lopez A.L., Valdes-Ramos R., Martinex-Carrillo B.E. T2DM, PUFAs, and vitamin D: their relation to inflammation. J Immunol Res 2014, 2014:860703. http://dx.doi.org/10.1155/2014/860703.
84. Cannell J.J., Hollis B.W. Use of vitamin D in clinical practice. Altern Med Rev 2008, 13(1):6-20.
85. Davidson M.B., Duran P., Lee M.L., Friedman T.C. High-dose vitamin D supplementation in people with prediabetes and hypovitaminosis D. Diabetes Care 2013, 36(2):260-266. http://dx.doi.org/10.2337/dc12-1204.
86. Schwalfenberg G. Vitamin D, and diabetes: improvement of glycemic control with vitamin D3 repletion. Can Fam Physician 2008, 54:864-866.
87. Kim D.J., Xun P., Liu K., et al. Magnesium intake in relation to systemic inflammation, insulin resistance, and the incidence of diabetes. Diabetes Care 2010, 33(12):2604-2610. http://dx.doi.org/10.2337/dc10-0994.
88. Guerrero-Romero F., Tamez-Perez H.E., González-González G., et al. Oral magnesium supplementation improves insulin sensitivity in non-diabetic subjects with insulin resistance. A double-blind placebo-controlled randomized trial. Diabetes Metab 2004, 30(3):253-258.
89. Rodríguez-Morán M., Guerrero-Romero F. Oral magnesium supplementation improves insulin sensitivity and metabolic control in type 2 diabetic subjects: a randomized double-blind controlled trial. Diabetes Care 2003, 26(4):1147-1152.
90. Song Y., He K., Levitan E.B., Manson J.E., Liu S. Effects of oral magnesium supplementation on glycaemic control in type 2 diabetes: a meta-analysis of randomized double-blind controlled trials. Diabet Med 2006, 23(10):1050-1056.
91. Mooren F.C., Krüger K., Völker K., Golf S.W., Wadepuhl M., Kraus A. Oral magnesium supplementation reduces insulin resistance in non-diabetic subjects-a double-blind, placebo-controlled, randomized trial. Diabetes Obes Metab 2011, 13(3):281-284.
92. Aggarwal B.B. Targeting inflammation induced obesity and metabolic diseases by curcumin and other nutraceuticals. Annu Rev Nutr 2010, 30:173-179.
93. Alappat L., Awad A.B. Curcumin and obesity: evidence and mechanisms. Nutr Rev 2010, 68(12):729-738.
94. Gonzales A.M., Orlando R.A. Curcumin and resveratrol inhibit nuclear factor-kappaB-mediated cytokine expression in adipocytes. Nutr Metab 2008, 5:17. http://dx.doi.org/10.1186/1743-7075-5-17
95. Sahebkar A. Why it is necessary to translate curcumin into clinical practice for the prevention and treatment of metabolic syndrome?. Biofactors 2012, http://dx.doi.org/10.1002/ biof.1062[Epub ahead of print].
96. Hsu C.H., Cheng A.L. Clinical studies with curcumin. Adv Exp Med Biol 2007, 595:471-480.
97. Chuengsamarn S., Rattanamongkolgul S., Luechapudiporn R., Phisalaphong C., Jirawatnotai S. Curcumin extract for prevention of type 2 diabetes. Diabetes Care 2012, 35(11):2121-2127.
98. Jurenka J.S. Anti-inflammatory properties of curcumin, a major constituent of curcuma longa: a review of preclinical and clinical research. Altern Med Rev 2009, 14(2):141-153.
99. Leach M. Gymnema sylvestre for diabetes mellitus: a systematic review. J Altern Complement Med 2007, 13(9):977-983.
100. Chattopadhyay R. A comparative evaluation of some blood sugar lowering agents of plant origin. J Ethnopharmacol 1999, 67:367-372.
101. Nahas R., Moher M. Complementary and alternative medicine for the treatment of type 2 diabetes. Can Fam Physician 2009, 55:591-596.
102. Vanadium/Vanadyl sulfate: monograph. Altern Med Rev 2009, 14:17-80.
103. Boden G., Chen X., Ruiz J., et al. Effects of vanadyl sulfate on carbohydrate and lipid metabolism in patients with non-insulin-dependent diabetes mellitus. Metabolism 1996, 45:1130-1135.
104. Jacques-Camarena O., González-Ortiz M., Martínez-Abundis E., et al. Effect of vanadium on insulin sensitivity in patients with impaired glucose tolerance. Ann Nutr Metab 2008, 53:195-198.
105. Vincent J.B. The biochemisty of chromium. J Nutr 2000, 130:715-718.
106. Anderson R.A. Chromium and insulin resistance. Nutr Res Rev 2003, 16:267-275.
107. Vincent J.B. Chromium: celebrating 50 years as an essential element?. Dalton Trans 2010, 39:3787-3794.
108. Office of Dietary Supplements. [Internet]. Dietary supplement fact sheet: Chromium. Washington, DC: United States Department of Health and Human Services. Reviewed November 4, 2013. http://ods.od.nih.gov/factsheets/chromium/.
109. Anderson R.A. Chromium, glucose intolerance and diabetes. J Am Coll Nutr 1998, 17(6):548-555.
110. Cefalu W.T., Rood J., Patricia Pinsonat P., et al. Characterization of the metabolic and physiologic response to chromium supplementation in subjects with type 2 diabetes mellitus. Metab Clin Exp 2010, 59:755-762.
111. Heimbach J.T., Anderson R.A. Chromium: recent studies regarding nutritional roles and safety. Nutr Today 2005, 40(4):180-195.
112. Shay K.P., Moreau R.F., Smith E.J., Smith A.R., Hagen T.M. Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential. Biochim Biophys Acta 2009, 1790:1149-1160.
113. Morikawa T., Yasuno R., Wada H. Do mammalian cells synthesize lipoic acid? Identification of a mouse cDNA encoding a lipoic acid synthase located in mitochondria. FEBS Lett 2001, 498:16-21.
114. Singh U., Jialal I. Alpha-lipoic acid supplementation and diabetes. Nutr Rev 2008, 66(11):646-657.
115. Padmalayam I., Hasham S., Saxena U., Pillarisetti S. Lipoic acid synthase (LASY): a novel role in inflammation, mitochondrial function, and insulin resistance. Diabetes 2009, 58:600-608.
116. Capasso I., Esposito E., Maurea N., et al. Combination of inositol and alpha lipoic acid in metabolic syndrome-affected women: a randomized placebo-controlled trial. Trial 2013, 14:273. http://dx.doi.org/10.1186/1745-6215-14-273
117. Udupa A., Nahar P., Shah S., et al. A comparative study of effects of omega-3 fatty acids, alpha lipoic acid and vitamin E in T2DM. Ann Med Health Sci Res 2013, 3(3):442-446.